During the past decade, Johannes Wesling Klinikum Minden; Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 5 clinical trials were completed, i.e. on average, 71.4% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Johannes Wesling Klinikum Minden; Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin" #1 collaborator was "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Frontier Science & Technology Research Foundation, Inc." with 1 trials as a collaborator and "Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Johannes Wesling Klinikum Minden; Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin" are "Multiple Myeloma" (2 trials), "Advanced BRAFV600 Wild-type Melanoma" (1 trials), "Lymphoma" (1 trials), "Malignant Melanoma" (1 trials) and "Non-Small Cell Lung Cancer (NSCLC)" (1 trials). Many other conditions were trialed in "Johannes Wesling Klinikum Minden; Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin" in a lesser frequency.

Most popular intervention types in "Johannes Wesling Klinikum Minden; Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin" are "Drug" (9 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (3 trials), "Bortezomib" (2 trials), "Dexamethasone" (2 trials), "Lenalidomide" (2 trials) and "Paclitaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "Johannes Wesling Klinikum Minden; Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Johannes Wesling Klinikum Minden; Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Johannes Wesling Klinikum Minden; Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Johannes Wesling Klinikum Minden; Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".